Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F9 | P00740 | 7/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | ESRRG | P62508 | 1/20 | 0.39 |
| ▸ | F7 | P08709 | 5/20 | 0.38 |
| ▸ | F3 | P13726 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL336042 | 0.89 | F9 (0.48) | F9MAPTSMN1; SMN2ESRRGF7 | |
| SCHEMBL335293 | 0.89 | F9 (0.48) | F9MAPTSMN1; SMN2ESRRGF7 | |
| SCHEMBL335988 | 0.87 | F9 (0.44) | F9MAPTESRRGF7F3 | |
| SCHEMBL335885 | 0.86 | F9 (0.43) | F9MAPTSMN1; SMN2ESRRGF7 | |
| SCHEMBL335731 | 0.86 | F9 (0.47) | F9MAPTESRRGF7F3 | |
| SCHEMBL335372 | 0.86 | F9 (0.43) | F9MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL336900 | 0.86 | F9 (0.47) | F9MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL336152 | 0.85 | F9 (0.46) | F9MAPTESRRGF7F3 | |
| SCHEMBL336541 | 0.84 | ALDH1A1 (0.47) | F9MAPTNPC1RAB9ATP53 | |
| SCHEMBL10165205 | 0.84 | MAPT (0.37) | F9MAPTSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097758-B2 | Isoserine derivatives for use as coagulation factor IXa inhibitors | SANOFI-AVENTIS (FR) | 2012-01-17 | — | — | US | claimed |
| US-20090233949-A1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | US | claimed |
| EP-2069289-B1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS | SANOFI SA (FR) | 2013-10-02 | — | — | EP | disclosed |
| US-8097758-B2 | Isoserine derivatives for use as coagulation factor IXa inhibitors | SANOFI-AVENTIS (FR) | 2012-01-17 | — | — | US | disclosed |
| US-8097758-B2 | Isoserine derivatives for use as coagulation factor IXa inhibitors | SANOFI-AVENTIS (FR) | 2012-01-17 | — | — | US | disclosed |
| US-8097758-B2 | Isoserine derivatives for use as coagulation factor IXa inhibitors | SANOFI-AVENTIS (FR) | 2012-01-17 | — | — | US | disclosed |
| US-20090233949-A1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233949-A1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233949-A1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-2069289-A1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS | Sanofi-Aventis (FR) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008031509-A1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS | SANOFI-AVENTIS (FR) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233949-A1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS | TFPI, F2, F9 | F9 3/4885MAPT 3998/4885SMN1; SMN2 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.